1. Home
  2. NTLA vs PGY Comparison

NTLA vs PGY Comparison

Compare NTLA & PGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

N/A

Current Price

$12.72

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Logo Pagaya Technologies Ltd.

PGY

Pagaya Technologies Ltd.

HOLD

Current Price

$22.96

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTLA
PGY
Founded
2014
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
NTLA
PGY
Price
$12.72
$22.96
Analyst Decision
Buy
Strong Buy
Analyst Count
23
8
Target Price
$20.02
$34.50
AVG Volume (30 Days)
3.1M
2.1M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
27.43
116.43
EPS
N/A
0.77
Revenue
$67,671,000.00
$1,301,360,000.00
Revenue This Year
N/A
$14.27
Revenue Next Year
$62.75
$14.39
P/E Ratio
N/A
$29.88
Revenue Growth
16.92
26.07
52 Week Low
$7.95
$10.40
52 Week High
$28.24
$44.99

Technical Indicators

Market Signals
Indicator
NTLA
PGY
Relative Strength Index (RSI) 51.41 62.25
Support Level $12.55 $20.44
Resistance Level $13.88 $23.22
Average True Range (ATR) 0.66 1.15
MACD 0.06 -0.08
Stochastic Oscillator 53.28 83.78

Price Performance

Historical Comparison
NTLA
PGY

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About PGY Pagaya Technologies Ltd.

Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.

Share on Social Networks: